Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
2024年5月29日 - 9:05PM
ビジネスワイヤ(英語)
– Exceptional biotech executive brings more
than 32 years of leadership to Vir –
– Deep knowledge in immunology and infectious
disease with proven track record of bringing late-stage clinical
development candidates into market –
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark
D. Eisner, M.D., M.P.H. will join the company as Executive Vice
President and Chief Medical Officer (CMO), effective June 03, 2024.
Dr. Eisner will be a part of the company’s Executive Management
Team and will report directly to Marianne De Backer, M.Sc., Ph.D.,
MBA, Vir’s Chief Executive Officer.
Dr. Eisner comes from Sonoma Biotherapeutics, Inc., where he
most recently held the position of CMO. In this role, he led all
development functions which included biometrics, regulatory,
clinical science, clinical operations, drug safety, and
pharmacology. Prior to his most recent tenure with Sonoma
Biotherapeutics, Dr. Eisner served as CMO at FibroGen where he led
all development functions, which included being the Head of China
clinical development and clinical operations. Dr. Eisner has also
been with Genentech nearly 11 years and served as their Senior Vice
President of Global Head of Product Development Immunology,
Infectious Disease and Ophthalmology and was accountable for
late-stage clinical development of many products including
strategy, clinical trials and budget. He brings to Vir deep
immunology and infectious disease expertise with clinical
development experience. Dr. Eisner has an impressive track record
of leading teams during times of strategically evolving
portfolios.
“We are delighted to welcome Mark, a seasoned and highly
respected scientist, clinician, and leader, to Vir’s Executive
Management Team. His exceptional leadership skills with late-stage
clinical experience and deep knowledge of immunology and infectious
disease will be critical to the next phase of Vir’s growth,” said
Dr. De Backer. “In addition to his proven track record of
overseeing multiple products across various indications while
securing breakthrough therapy designation, Mark’s visionary and
enterprise mindset will be of great benefit to Vir as we focus on
bringing medicine to patients with unmet medical needs.”
Dr. Eisner completed his A.B. degree in human biology at
Stanford University and his M.D. degree at the University of
Pennsylvania School of Medicine. He also has an M.P.H. focusing on
epidemiology from the University of California Berkeley, School of
Public Health. He has an impressive list of publications and
patents, honors and awards, and services for professional
organizations.
“I am thrilled to be joining Vir at this critical time and am
looking forward to working with the talented teams to advance our
clinical development programs,” said Dr. Eisner. “I have always
admired the bold mission of the company. Patients have always been
my guiding compass, so I am excited to have this opportunity to
help translate Vir’s groundbreaking science into advances for human
health.”
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on
powering the immune system to transform lives by treating and
preventing infectious diseases and other serious conditions,
including viral-associated diseases. Vir has assembled two
technology platforms that are designed to modulate the immune
system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis delta and hepatitis B
viruses, and human immunodeficiency virus. Vir has several
preclinical candidates in its pipeline, including those targeting
influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “plan,” “potential,” “aim,”
“expect,” “anticipate,” “promising” and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on Vir’s expectations and assumptions as of the date of this
press release. Forward-looking statements contained in this press
release include, but are not limited to, statements regarding Vir’s
strategy and plans, the potential clinical effects of tobevibart
and elebsiran, the potential benefits, safety and efficacy of
tobevibart and elebsiran, the timing, nature and significance of
data from Vir’s multiple ongoing trials evaluating tobevibart and
elebsiran, including the SOLSTICE data, the timing of any further
releases of data or of any presentations or investor conference
calls, Vir’s plans and expectations for its CHD and CHB programs,
and risks and uncertainties associated with drug development and
commercialization. Many factors may cause differences between
current expectations and actual results, including unexpected
safety or efficacy data or results observed during clinical trials
or in data readouts; the occurrence of adverse safety events; risks
of unexpected costs, delays or other unexpected hurdles;
difficulties in collaborating with other companies; successful
development and/or commercialization of alternative product
candidates by Vir’s competitors; changes in expected or existing
competition; delays in or disruptions to Vir’s business or clinical
trials due to geopolitical changes or other external factors; and
unexpected litigation or other disputes. Drug development and
commercialization involve a high degree of risk, and only a small
number of research and development programs result in
commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these statements,
or the scientific data presented. Other factors that may cause
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Vir’s filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as required by law, Vir assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529079100/en/
Media Carly Scaduto Senior Director, External
Communications cscaduto@vir.bio +1 314-368-5189
Investors Richard Lepke Senior Director, Investor
Relations rlepke@vir.bio +1 978-973-9986
Vir Biotechnology (NASDAQ:VIR)
過去 株価チャート
から 5 2024 まで 6 2024
Vir Biotechnology (NASDAQ:VIR)
過去 株価チャート
から 6 2023 まで 6 2024